Halozyme gains as U.S. and EU clear Enhanze based products

kemalbas/iStock via Getty Images Halozyme ( NASDAQ: HALO ) shares traded higher on Tuesday after the company said two therapeutic formulations based on its Enhanze drug delivery technology were approved in the U.S. and Europe. In the U.S., Takeda ( TAK ) won FDA approval for Hyqvia as a treatment for adults with a neurological disorder called chronic inflammatory demyelinating polyneuropathy (CIDP).

Hyqvia, co formulated with Enhanze, will be indicated as a subcutaneously delivered antibody infusion to prevent the relapse of neuromuscular disability and impairment in adults with CIDP. Meanwhile, in Europe, Roche ( OTCQX:RHHBF ) ( OTCQX:RHHBY ) has received the European Commission’s marketing authorization for Tecentriq SC.

Therefore, the subcutaneous formulation based on Enhanze will be indicated for all approved indications applicable for intravenous Tecentriq. The approval marks Europe’s first PD L1 cancer immunotherapy indicated for subcutaneous injection. More on Halozyme Therapeutics Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway Halozyme Therapeutics, Inc.

(HALO) Q3 2023 Earnings Call Transcript Halozyme Therapeutics, Inc. 2023 Q3 Results Earnings Call Presentation JNJ multiple myeloma therapy outperforms standard of care by 58% argenx slips as autoimmune disorder therapy fails in pivotal trial.